Calcitonin salmon is a synthetic version of a hormone naturally produced by salmon that suppresses bone breakdown and is approved for Paget's disease, hypercalcemia, and postmenopausal osteoporosis when other treatments aren't suitable.
What it does
Calcitonin salmon is a calcitonin receptor agonist — meaning it binds to and activates the same receptors that respond to your body's own calcitonin hormone. Its primary target is bone tissue, where calcitonin receptors sit on osteoclasts (the cells that break bone down) and osteoblasts (the cells that build bone up). By activating these receptors, the drug slows bone resorption (the breakdown and release of minerals from bone into the bloodstream) PubMed 9473255. The salmon-derived version is used rather than mammalian calcitonin because it binds more potently and stays active longer per milligram PubMed 10969448.
Beyond bone, calcitonin salmon also acts on the kidneys to increase calcium and phosphate excretion — useful when blood calcium climbs dangerously high — and has recognized effects on the gastrointestinal tract, though those are less clinically relevant PubMed 8587058. The full picture of how calcitonin interacts with normal bone physiology in humans hasn't been completely worked out, but its clinical effects on reducing bone turnover are well established.
What the evidence shows
Paget's disease of bone Established clinical use; approved indication with decades of clinical experience
Paget's disease is a chronic disorder in which bone remodeling goes haywire — certain bones break down and regrow abnormally, becoming enlarged and structurally weak. Calcitonin salmon is indicated for symptomatic, moderate-to-severe cases involving multiple bones with elevated serum markers of bone turnover. It reduces those markers and relieves bone pain, though it has largely been displaced by bisphosphonates in first-line practice PubMed 10969448. It remains an option when bisphosphonates aren't tolerated or appropriate.
Hypercalcemia Established clinical use; approved for acute management
Hypercalcemia — abnormally high calcium in the blood — can result from malignancy, hyperparathyroidism, or prolonged immobility. Calcitonin salmon lowers serum calcium quickly by suppressing osteoclast activity and increasing renal calcium excretion PubMed 9473255. Its onset is faster than bisphosphonates, making it useful for acute cases, though tachyphylaxis (rapid loss of drug effect with repeated dosing) limits its usefulness beyond the first 48–72 hours of treatment.
Postmenopausal osteoporosis Approved indication, but fracture reduction efficacy not demonstrated; concerns about malignancy risk with long-term use
Calcitonin salmon is approved as a second-line option for postmenopausal osteoporosis when alternatives — bisphosphonates, estrogen, or RANK-L inhibitors — aren't suitable. It increases bone mineral density modestly, and nasal spray formulations have shown some evidence of vertebral fracture reduction, though injectable forms have not demonstrated this PubMed 10811300. Notably, the FDA label explicitly states fracture reduction efficacy has not been demonstrated for the injection. A pooled analysis also flagged a possible association between long-term calcitonin use and malignancy, which is why continued therapy requires periodic re-evaluation PubMed 24357414.
Delivery and bioavailability research Mostly preclinical; animal models and early-phase human pharmacokinetic studies
Because calcitonin salmon is a peptide, getting it into the body via non-injectable routes is difficult — stomach acid degrades it quickly. Several research groups have explored oral emulsion formulations PubMed 11123497, buccal (cheek) transmucosal delivery PubMed 12523672, and other transmucosal systems PubMed 10811300, with mixed results in animals and limited human data. Food and water intake meaningfully affect oral formulation pharmacokinetics NCT00395395. Intramuscular injection remains the most reliable delivery route for consistent bioavailability PubMed 10969448.
How it's used
In studies and approved clinical protocols, calcitonin salmon injection is administered intramuscularly (IM) or subcutaneously. The dose is 0.5 mL per injection, though the frequency and total dose vary by indication — Paget's disease, hypercalcemia, and osteoporosis each follow different titration schedules per prescribing guidelines. The half-life is 59–64 minutes PubMed 10969448, so dosing is typically daily or several times per week depending on the clinical goal. Skin testing for hypersensitivity before the first dose is recommended given the risk of anaphylaxis. Nasal spray formulations exist for osteoporosis but are distinct from the injectable form discussed here.
Side effects and safety
The most common reported side effects are nausea and injection site reactions (redness, swelling, discomfort), which tend to be mild and often improve with continued use. Vomiting occurs less frequently. The most serious risk is anaphylaxis — a severe, potentially life-threatening allergic reaction — which has resulted in deaths; bronchospasm and throat or tongue swelling have also been reported PubMed 9473255. Anyone with a known hypersensitivity to calcitonin salmon or its excipients (inactive ingredients) should not use it. A long-term safety concern flagged in pooled data is a possible association between calcitonin use and certain malignancies; this hasn't been definitively proven causal, but it's taken seriously enough that ongoing therapy requires periodic reassessment of benefit vs. risk. Long-term data in humans is limited, and the malignancy signal remains incompletely characterized PubMed 24357414.
Bottom line
Calcitonin salmon is a well-established but increasingly second-line drug — useful for Paget's disease and acute hypercalcemia, and available for osteoporosis when newer agents aren't an option, but without proven fracture reduction in injectable form. The unresolved malignancy signal with long-term use means it's not a casual choice. It's best suited for patients who have exhausted or can't tolerate first-line bone therapies.